No breakthroughs this week, but still plenty of lesser news, and a bit of bogosity. I have no idea why anyone would be possessed to ignore CGMs in a study of digital diabetes tools.
Fierce Healthcare: Digital diabetes tools don't deliver meaningful benefits: study
A new analysis pours cold water on the effectiveness of widely used digital diabetes management solutions, stirring up discussion about how best to evaluate the growing market of digital health tools.The Digital Therapeutics Alliance, which includes DarioHealth as one of its members, said in a statement that it supports the PHTI's "overarching methodology" but disagrees with the conclusions drawn.
DTx noted the lack of endocrinologists among the clinical advisers who contributed and reviewed the report, and the trade group argued the report made a "sweeping conclusion" on all diabetes products based on a small sample size.
[Omar Manejwala, M.D., chief medical officer at DarioHealth,] also took issue with the PHTI issuing a patient guide (PDF) for digital diabetes solutions based on what he called a "flawed analysis."
The report highlighted one "promising solution" out of the eight that were evaluated—Virta Health's. The company's solution aims to reverse Type 2 diabetes through personalized nutrition therapy and remote medical care.
This is not what I recognize as a digital health tool.
The study concluded that digital diabetes tools don't improve patients' health and increase overall spending.